Bristol Myers cell therapy for multiple myeloma meets main goal
Bristol Myers Squibb said its experimental cell therapy arlocabtagene autoleucel (arlo-cel) met the main goal in a mid-stage trial in patients with a hard-to-treat form of multiple myeloma.
Bristol Myers Squibb NYSE:BMY said on Tuesday that its experimental cell therapy met the main goal of a mid-stage trial. The therapy, arlocabtagene autoleucel, or arlo-cel, was being tested in patients with a hard-to-treat form of multiple myeloma, a type of blood cancer.